Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

Volume: 39, Issue: 6, Pages: 524 - 531
Published: Dec 1, 2013
Abstract
null Aims/hypothesis null This study was conducted to determine the optimal monthly subcutaneous dose of canakinumab (a human monoclonal anti-human IL-1β antibody) needed to improve glucose control in metformin-treated patients with type 2 diabetes mellitus (T2DM). null Methods null This was a parallel-group, randomized, double-blind, multicentre, placebo-controlled study designed to assess the effect on HbA 1c null and the safety/tolerability...
Paper Details
Title
Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial
Published Date
Dec 1, 2013
Volume
39
Issue
6
Pages
524 - 531
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.